Pharmaceuticals News

Browse the latest Pharmaceuticals news. Use the menu or navigation tiles to change industry or topic.

January 23, 2026 01:00 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse : L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique

L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique Dans l'étude de phase 3 SHORE, l'amlitelimab en association avec des traitements topiques a atteint tous les critères...
January 23, 2026 01:00 ET | Source: Sanofi Winthrop Industrie

Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis

Sanofi's amlitelimab confirms its potential in atopic dermatitis In the SHORE phase 3 study, amlitelimab in combination with topical therapies met all primary and key secondary endpoints at Week 24...
January 22, 2026 17:00 ET | Source: Vaxcyte, Inc.

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study...
January 22, 2026 16:05 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

SAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating...
January 22, 2026 16:05 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic...
January 22, 2026 16:05 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
January 22, 2026 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference

Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ETArcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February...
January 22, 2026 13:42 ET | Source: Psyence Biomedical Ltd.

Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026

NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that it adjourned its annual and special meeting of shareholders...
January 22, 2026 12:00 ET | Source: Amoeba

Medalha d’ouro no SIVAL, Amoéba apresenta suas ambições para sua solução de biocontrolo

Chassieu, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Medalha d’ouro no SIVAL, Amoéba apresenta suas ambições para sua solução de biocontrolo Chassieu (França), 22 de janeiro 2026 – 18h00 - Amoéba...
January 22, 2026 12:00 ET | Source: Amoeba

Gold medal winner at SIVAL, Amoéba displays its ambitions for its biocontrol solution

Chassieu, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Chassieu (France), 20 January 2026 – 6:00 pm - Amoéba (FR0011051598 - ALMIB), industrial greentech specialised in the development of natural...